Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$14.18
-0.2%		$14.40
$5.60
▼
$26.95
$1.19B0.872.04 million shs28,870 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.21
-0.1%		$19.36
$4.79
▼
$25.77
$1.21B1.51.36 million shs30,672 shs
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$4.63
+4.1%		$3.74
$1.24
▼
$5.81
$383.91M0.58946,527 shs765,237 shs
ODTX
Odyssey Therapeutics
$26.33
-1.1%		$20.08
$15.10
▼
$28.00
$1.27BN/A276,144 shs22,103 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.49%-3.60%+6.21%+21.16%+150.44%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-0.63%-1.11%-7.54%-18.09%+189.02%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
+16.19%+17.11%+22.25%-4.09%+261.79%
ODTX
Odyssey Therapeutics
+8.65%+3.90%+46.83%+56.59%+2,661,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$14.18
-0.2%		$14.40
$5.60
▼
$26.95
$1.19B0.872.04 million shs28,870 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.21
-0.1%		$19.36
$4.79
▼
$25.77
$1.21B1.51.36 million shs30,672 shs
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$4.63
+4.1%		$3.74
$1.24
▼
$5.81
$383.91M0.58946,527 shs765,237 shs
ODTX
Odyssey Therapeutics
$26.33
-1.1%		$20.08
$15.10
▼
$28.00
$1.27BN/A276,144 shs22,103 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-0.49%-3.60%+6.21%+21.16%+150.44%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-0.63%-1.11%-7.54%-18.09%+189.02%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
+16.19%+17.11%+22.25%-4.09%+261.79%
ODTX
Odyssey Therapeutics
+8.65%+3.90%+46.83%+56.59%+2,661,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$33.33134.74% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.78
Moderate Buy$28.50100.42% Upside
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
2.89
Moderate Buy$10.69140.28% Upside
ODTX
Odyssey Therapeutics
2.63
Moderate Buy$35.7534.30% Upside

Current Analyst Ratings Breakdown

Latest IRD, GLUE, CRVS, and ODTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/25/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$28.00
8/24/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/11/2026
ODTX
Odyssey Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/11/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/7/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$10.00 ➝ $9.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$35.00 ➝ $28.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$31.00 ➝ $27.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$29.00 ➝ $27.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share112.58$2.68 per shareN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$28.73M42.23N/AN/A$5.71 per share2.49
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$14.20M25.90N/AN/A($0.16) per share-27.81
ODTX
Odyssey Therapeutics
N/AN/AN/AN/A$8.76 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.61N/AN/AN/AN/A-36.15%-33.62%11/3/2026 (Estimated)
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$38.63M-$1.76N/AN/AN/A-560.85%-43.31%-27.59%11/5/2026 (Estimated)
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$49.59M-$1.35N/AN/AN/A-1,091.82%-338.88%-150.13%11/11/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A

Latest IRD, GLUE, CRVS, and ODTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1591-$0.19-$0.0309-$0.19N/AN/A
8/6/2026Q2 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.3805-$0.43-$0.0495-$0.43$12.91 million$8.97 million
8/6/2026Q2 2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.1567-$0.14+$0.0167-$0.14$2.63 million$0.76 million
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
6/17/2026Q1 2026
ODTX
Odyssey Therapeutics
-$1.31-$6.77-$5.46-$6.77N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
16.16
16.16
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
10.58
10.58
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/A
12.19
12.19
ODTX
Odyssey Therapeutics
N/A
11.36
11.36

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
14.97%
ODTX
Odyssey Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.40%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
11.70%
ODTX
Odyssey Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3084.12 million67.55 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9085.31 million79.85 millionOptionable
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1482.65 million72.98 millionN/A
ODTX
Odyssey Therapeutics
N/A48.06 millionN/AN/A

Recent News About These Companies

What is HC Wainwright's Estimate for ODTX Q3 Earnings?
August 31 at 1:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993274
Q3 Earnings Forecast for ODTX Issued By HC Wainwright
August 31 at 1:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q3-earnings-forecast-for-odtx-issued-by-hc-wainwright-2026-08-31/
Odyssey Therapeutics (NASDAQ:ODTX) Research Coverage Started at HC Wainwright
August 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991455
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351300/0/en/odyssey-therapeutics-to-participate-in-upcoming-investor-conferences.html
Odyssey Therapeutics Inc.
August 18, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/odtx/financials
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co.
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/odyssey-therapeutics-nasdaqodtx-given-new-2900-price-target-at-jpmorgan-chase-co-2026-08-07/
Odyssey Therapeutics: Q2 Earnings Snapshot
August 6, 2026  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q2-earnings-snapshot-22376823.php
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evotec-and-odyssey-therapeutics-enter-ai-enabled-rd-collaboration-in-autoimmune-and-inflammatory-diseases-302844665.html
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338150/0/en/odyssey-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics Stock Price History
July 16, 2026  |  investing.comhttps://www.investing.com/equities/odyssey-therapeutics-inc-historical-data
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc Share Price (ODTX.US)
July 6, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=ODTX.US
Odyssey Therapeutics: Q1 Earnings Snapshot
June 18, 2026  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q1-earnings-snapshot-22310114.php
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/odyssey-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics Inc
May 26, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/odtx-odyssey-therapeutics-inc
A Boston biotech tried to go public last year but pulled back. Now it’s valued at nearly $1B
May 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/boston-biotech-tried-public-last-165524528.html
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) Major Shareholder Buys 1,388,889 Shares of Stock
May 14, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-14/
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) Director Buys $19,999,998.00 in Stock
May 13, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-13/
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
May 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/healthcare-ipos-raise-4-7-123114761.html
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) CFO Acquires 1,000 Shares of Stock
May 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-12/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Nvidia logo illuminated in green on a circuit board background with glowing data connection lines.
NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270
By Thomas Hughes | August 14, 2026
AST SpaceMobile promotional graphic featuring the company logo, a satellite, and Earth from orbit.
AST SpaceMobile’s Latest BlueBird Launch Raises the Stakes Ahead of Q2 Earnings
By Jessica Mitacek | August 7, 2026
AST SpaceMobile logo with satellite in orbit beaming signals down to an illuminated Earth at night.
AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
By Jessica Mitacek | August 11, 2026
Amazon delivery worker in branded vest holding a Prime package at a customer's front door.
A Star Investor Just Trimmed Amazon—Here's What It means
By Sam Quirke | August 18, 2026
Illuminated Pathward logo displayed on a wall in a corporate office reception area with glass doors.
Pathward’s Credit Scare Tests Its Comeback Story
By Peter Frank | August 25, 2026
Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$14.18 -0.02 (-0.16%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$14.21 -0.01 (-0.06%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Opus Genetics stock logo

Opus Genetics NASDAQ:IRD

$4.63 +0.18 (+4.13%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Odyssey Therapeutics NASDAQ:ODTX

$26.33 -0.29 (-1.09%)
As of 10:02 AM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas